NIH research clears way for study of experimental treatment for opioid use disorder
Clinical Scorecard: NIH Advances Research on Investigational Treatment for Opioid Use Disorder
At a Glance
| Category | Detail |
|---|
| Condition | Opioid Use Disorder |
| Key Mechanisms | Mitragynine, a kratom isolate, interacts with opioid receptors; potential therapeutic effects driven by slow conversion in the body. |
| Target Population | Individuals with opioid use disorder |
| Care Setting | Clinical trial setting |
Key Highlights
- IND application for mitragynine has taken effect with the FDA.
- NIH-led phase I clinical trial to evaluate safety and tolerability of mitragynine.
- Preclinical studies showed no significant safety concerns in animal models.
- First randomized, double-blind, placebo-controlled study planned.
- Part of the NIH HEAL Initiative.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Millions of Americans struggling with opioid use disorder.
Mitragynine has been used for opioid withdrawal and pain.
Clinical Best Practices
- Conduct randomized, double-blind, placebo-controlled studies to assess new treatments.
Related Resources & Content
